biOasis Provides Scientific Updates on Its Transcend Programs

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 12, 2015) - BIOASIS TECHNOLOGIES INC. (TSX VENTURE:BTI)(OTCQX:BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), has announced results from its Her2+ brain tumor model with its lead therapeutic, MTfp-TZM. The company has also provided a scientific update relating to other programs.

The biOasis Neuro-Oncology Program

biOasis has completed efficacy and other tests using Her2+ brain tumor animal models using its lead BBB delivery vectors melanotransferrin (MTf) and melanotransferrin-peptide(MTfp) to deliver the anti-cancer drug, trastuzumab (TZM) across the blood-brain barrier (BBB). Fusion proteins comprised of the cancer drug trastuzumab (TZM or Herceptin) and MTf (MTf-TZM) or MTfp (MTfp-TZM) were used. The purpose of these studies was to answer specific questions and provide data relating to taking MTfp-TZM into clinical trials. As a result of the combined studies and with the benefit of the full collection of data, the biOasis Board of Directors supports moving MTfp-TZM to an IND and into clinical trials.

The recent results revealed that MTfp-TZM showed increased activity against Her2+ brain tumors when compared to other Transcend/trastuzumab conjugates that biOasis has previously tested. MTfp-TZM reduced the size and number of brain tumors in the animal models and showed improved activity levels outside the brain compared to TZM alone. Statistically significant increased animal survival rates were also observed compared to the controls. An additional dose titration study confirmed tolerance at levels equal to that of current dosing in humans.

Commented CEO, Rob Hutchison, "We're very pleased with the latest results of the MTf-and MTfp-trastuzumab studies. MTfp-TZM met or exceeded our objectives with the key data confirming the enhanced activity of the fusion protein and as a result, our Board of Directors has placed a high priority on moving MTfp-TZM into the clinic. Until submissions are made to clinical regulators and to scientific publications, biOasis will not be releasing quantitative data from the studies, but may do so at an appropriate time in the future."